Business Standard

Will pharma stocks continue their dream rally in FY25?

PRESCRIPTION FOR CAUTION: Analysts sound alarm on valuations after past year's recovery

pharma medicine drugs
Premium

Shivam Tyagi New Delhi

Listen to This Article

Stocks in the pharmaceutical (pharma) sector have had a dream run so far in 2023-24 (FY24), with the National Stock Exchange Nifty Pharma Index surging 58.2 per cent in this period against a dip of 11 per cent in 2022-23 (FY23), reveals Ace Equity data. The index has also outperformed the Nifty50, which grew by 28.7 per cent in the current financial year.

Among stocks, Orchid Pharma gave a handsome return of 210 per cent, followed by Lupin’s 157 per cent jump so far in 2023-24 (FY24).

Others like Suven Life Sciences, Venus Remedies, and Aurobindo Pharma saw 127 per

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in